



FOR IMMEDIATE RELEASE

### **OriGene and Cytomyx Collaborate to Develop New Biomarker Validation Technologies**

Rockville, MD October 17, 2005 – OriGene Technologies Inc. today announced they have entered into an agreement with Cytomyx Holdings, PLC to co-develop new tools to profile gene expression and biomarker validation in a range of human cancers.

Under the terms of the agreement, Cytomyx will supply hundreds of highly characterized RNA samples from a wide range of major cancers from its extensive Biorepository. OriGene will use these samples to develop new generations of their existing Rapid-Scan Gene Expression Panel product line. The new Rapid-Scan panels will enable researchers to profile gene expression levels in these patient derived samples to determine linkages between gene expression and tumor occurrence and development. Cytomyx also intends to develop complementary tissue microarrays (TMAs), which can be used to further investigate these linkages at the protein expression level using immunohistochemistry.

"The development of this new high-throughput analysis system will enable researchers to rapidly assess gene expression levels across a wide range of patients with different forms and stages of the major cancers. As such we expect that it will become an important new resource in the effort to characterize tumors at the genetic level and may help in the development of precisely targeted new diagnostics and therapies in the future," said Mike Kerins, CEO of Cytomyx, "We are pleased to be working with OriGene who have established themselves as a leading developer of genetic research products. In particular their access to the global market for research products will help to ensure the success of this important new product line."

"Having a tool that demonstrates correlation of mRNA levels to detailed disease stages is critical for biomarker validation," said Rich Hamer, PhD, VP Business Development at OriGene. "OriGene's Rapid-Scan platform combined with the depth of Cytomyx' Biorepository greatly enhances the target screening and biomarker validation toolset needed by today's researchers."

#### **About Cytomyx Holdings**

Cytomyx Holdings plc is a rapidly growing life science company based in Cambridge, UK. The Company's primary focus is on developing novel technologies that assist pharmaceutical and biotechnology companies in their efforts to develop new treatments more effectively. The company does this by providing solutions that provide early insights into the likely efficacy and safety profile of new drugs in development. The Company has two main areas of expertise: the use of human clinical samples in understanding the linkage between gene expression and disease and the development of cell-based assays that are used to support ion channel drug discovery and predict potential cardiac toxicity in new drugs. Cytomyx is listed on the AIM market of the London Stock Exchange (CYX.L). For more information visit [www.cytomyx-holdings.com](http://www.cytomyx-holdings.com)

#### **About OriGene Technologies**

OriGene provides innovative technologies for large-scale gene function analyses. OriGene's flagship products include the TrueClone Collection, a searchable source of over 24,000 human full-length cDNA clones suitable for transfection and protein expression, GFC-Arrays, arrayed sets of TrueClones suitable for high-throughput target validation and understanding of the causative role of genes in disease and Rapid-Scan, a set of panels for profiling gene expression levels and biomarker validation. More information about OriGene Technologies and their products can be found by visiting the company's web site at <http://www.origene.com>.

For additional information regarding this announcement, please contact:

**OriGene**

Six Taft Court, Rockville MD 20850 USA  
Rich Hamer, Ph.D. Business Development  
240-620-5781  
[rhamer@origene.com](mailto:rhamer@origene.com)

**Cytomyx**

6-7 Technopark, Cambridge, CB5 8PB, UK.  
Mike Kerins, CEO  
+44(0)1223 508191  
[mike.kerins@cytomyx.com](mailto:mike.kerins@cytomyx.com)